Revelation Biosciences, Inc.
(NASDAQ : REVB)

( )
REVB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.27%176.780.0%$746.14m
AMGNAmgen, Inc. 1.08%251.081.5%$612.30m
VRTXVertex Pharmaceuticals, Inc. 3.74%305.531.9%$437.49m
GILDGilead Sciences, Inc. 5.16%66.211.0%$435.11m
REGNRegeneron Pharmaceuticals, Inc. 2.32%643.292.6%$372.05m
ILMNIllumina, Inc. 8.77%226.593.3%$330.40m
SNSSSunesis Pharmaceuticals, Inc. 5.74%4.420.7%$308.97m
NVAXNovavax, Inc. 2.00%42.3075.7%$284.25m
BIIBBiogen, Inc. 0.63%222.381.8%$205.32m
BNTXBioNTech SE 1.33%162.480.0%$158.03m
GOVXGeoVax Labs, Inc. 1.59%2.550.0%$140.51m
BMRNBioMarin Pharmaceutical, Inc. 1.97%96.944.2%$104.96m
CRSPCRISPR Therapeutics AG 1.88%80.140.6%$104.75m
PACBPacific Biosciences of California, Inc. -4.89%8.366.2%$98.27m
MRTXMirati Therapeutics, Inc. -0.06%86.321.6%$96.84m

Company Profile

Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.